Parecoxib sodium pretreatment reduces myoclonus after etomidate

Parecoxib sodium pretreatment reduces myoclonus after etomidate: A prospective, double-blind, randomized clinical trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15007296

Enrollment

Unknown

Registered

2015-09-18

Start date

2015-10-19

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic cholecystitis

Interventions

Group P:Parecoxib sodium

Group S:Saline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are scheduled to undergo elective laparoscopic cholecystectomy under general anesthesia.

Exclusion criteria

Exclusion criteria: Patients are excluded from the study if have an allergy to the medications, serious cardiovascular system disease, liver or kidney dysfunction, coagulation disorders, or an upper respiratory infection.

Design outcomes

Primary

Measure	Time frame
The incidence of myoclonus;	—

Countries

China

Contacts

Public ContactXiuze Li

lxz123@126.com+86 13881130420

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026